GLP-1 Agonists are already approved for weight loss in individuals without diabetes, and ongoing studies suggest that GLP-1 therapies may have broader applications in treating conditions like metabolic syndrome, fatty liver disease, and cardiovascular health
A drug that reduces body weight by more than 20%, reduces liver fat substantially, improves glycemic control, and likely reduces cardiovascular events represents an intervention on the upstream causes of multiple age-related diseases simultaneously
The data behind the conviction Reason one is the growth engine
A study of humans with a genetic mutation for CYP2R1, or those done using CYP2R1 knockdown mouse models, demonstrate low circulating levels of 25(OH)VD 3 24
The cost and accessibility of these medications are other practical factors to keep in mind
A meta-analysis published in 2024 involving data from multiple randomized controlled trials found that patients taking GLP-1 receptor agonists had a statistically significant increased risk of developing DVT compared to control groups
